In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Micro Interventional Devices: Creating A Tool Box For Structural Heart Disease

Executive Summary

Micro Interventional Devices was founded around opportunities in addressing the procedural challenges that limit patient access to transcatheter heart valves. The company’s initial focus is on developing a transcatheter valve for the replacement of the mitral valve, and an easy and effective transapical access and closure method for transcatheter mitral and aortic valve procedures. The company’s mission, though, is to broadly focus on advancing structural heart disease treatments, and MID’s first-generation technology has potential application to several areas of structural heart disease, including PFO/atrial septal defect closure, left atrial appendage closure and cardiac ablations.

Advertisement

Related Content

Micro Interventional Devices’ Permaseal Moves Closer To Regulatory Approval With Early CE Trial Results
Micro Interventional Preps 2013 EU Launch For Transapical Access Device
Medical Device Start-Up News, August 2012
Percutaneous Mitral Valve Therapy: The Next Decade
The Latest On Transapical: Edwards Talks Up Sapien CAP Data
As TAVI Advances, Adjunctive Devices Multiply
Transapical Valve Technique Holds Its Own In Europe, Surgeons Say
Transcatheter Valves: Tough Love For Transapical Placement Method At TCT
Have Device VCs Bet Too Big?
Endovalve Inc.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel